Literature DB >> 15931395

Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide.

Karim Sabrane1, Markus N Kruse, Larissa Fabritz, Bernd Zetsche, Danuta Mitko, Boris V Skryabin, Melanie Zwiener, Hideo A Baba, Masashi Yanagisawa, Michaela Kuhn.   

Abstract

Atrial natriuretic peptide (ANP), via its vasodilating and diuretic effects, has an important physiological role in the maintenance of arterial blood pressure and volume. Its guanylyl cyclase-A (GC-A) receptor is highly expressed in vascular endothelium, but the functional relevance of this is controversial. To dissect the endothelium-mediated actions of ANP in vivo, we inactivated the GC-A gene selectively in endothelial cells by homologous loxP/Tie2-Cre-mediated recombination. Notably, despite full preservation of the direct vasodilating effects of ANP, mice with endothelium-restricted deletion of the GC-A gene (EC GC-A KO) exhibited significant arterial hypertension and cardiac hypertrophy. Echocardiographic and Doppler flow evaluations together with the Evan's blue dilution technique showed that the total plasma volume of EC GC-A KO mice was increased by 11-13%, even under conditions of normal dietary salt intake. Infusion of ANP caused immediate increases in hematocrit in control but not in EC GC-A KO mice, which indicated that ablation of endothelial GC-A completely prevented the acute contraction of intravascular volume produced by ANP. Furthermore, intravenous ANP acutely enhanced the rate of clearance of radio-iodinated albumin from the circulatory system in control but not in EC GC-A KO mice. We conclude that GC-A-mediated increases in endothelial permeability are critically involved in the hypovolemic, hypotensive actions of ANP.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15931395      PMCID: PMC1136988          DOI: 10.1172/JCI23360

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

1.  Left but not right cardiac hypertrophy in atrial natriuretic peptide receptor-deficient mice is prevented by angiotensin type 1 receptor antagonist losartan.

Authors:  Rita Holtwick; Hideo A Baba; Elisabeth Ehler; Dorothée Risse; Melanie Vobeta; Joseph Gehrmann; Melanie Pierkes; Michaela Kuhn
Journal:  J Cardiovasc Pharmacol       Date:  2002-11       Impact factor: 3.105

Review 2.  The physiological and pathophysiological modulation of the endocrine function of the heart.

Authors:  A J de Bold; K K Ma; Y Zhang; M L de Bold; M Bensimon; A Khoshbaten
Journal:  Can J Physiol Pharmacol       Date:  2001-08       Impact factor: 2.273

3.  Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A.

Authors:  P M Oliver; J E Fox; R Kim; H A Rockman; H S Kim; R L Reddick; K N Pandey; S L Milgram; O Smithies; N Maeda
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

4.  Microvascular hyperpermeability in caveolin-1 (-/-) knock-out mice. Treatment with a specific nitric-oxide synthase inhibitor, L-NAME, restores normal microvascular permeability in Cav-1 null mice.

Authors:  William Schubert; Philippe G Frank; Scott E Woodman; Hideyuki Hyogo; David E Cohen; Chi-Wing Chow; Michael P Lisanti
Journal:  J Biol Chem       Date:  2002-08-07       Impact factor: 5.157

5.  Guanylyl cyclase mediates ANP-induced vasoconstriction of murine splenic vessels.

Authors:  Peter S Andrew; Susan Kaufman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2003-02-06       Impact factor: 3.619

6.  Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A.

Authors:  Rita Holtwick; Martin van Eickels; Boris V Skryabin; Hideo A Baba; Alexander Bubikat; Frank Begrow; Michael D Schneider; David L Garbers; Michaela Kuhn
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

7.  The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance.

Authors:  David Vicent; Jacob Ilany; Tatsuya Kondo; Keiko Naruse; Simon J Fisher; Yaz Y Kisanuki; Sven Bursell; Masashi Yanagisawa; George L King; C Ronald Kahn
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

Review 8.  Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A.

Authors:  Michaela Kuhn
Journal:  Circ Res       Date:  2003-10-17       Impact factor: 17.367

9.  Hypervolemic hypertension in mice with systemic inactivation of the (floxed) guanylyl cyclase-A gene by alphaMHC-Cre-mediated recombination.

Authors:  Boris V Skryabin; Rita Holtwick; Larissa Fabritz; Markus N Kruse; Ilka Veltrup; Jörg Stypmann; Paulus Kirchhof; Karim Sabrane; Alexander Bubikat; Melanie Voss; Michaela Kuhn
Journal:  Genesis       Date:  2004-08       Impact factor: 2.487

10.  Morphology of the human and dog spleen with special reference to intrasplenic microcirculation.

Authors:  K Takubo; H Miyamoto; M Imamura; T Tobe
Journal:  Jpn J Surg       Date:  1986-01
View more
  56 in total

Review 1.  Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases.

Authors:  Lincoln R Potter
Journal:  Pharmacol Ther       Date:  2010-12-24       Impact factor: 12.310

2.  cGMP signalling: from bench to bedside. Conference on cGMP generators, effectors and therapeutic implications.

Authors:  Robert Feil; Barbara Kemp-Harper
Journal:  EMBO Rep       Date:  2006-02       Impact factor: 8.807

3.  Phosphodiesterase 4 inhibition attenuates atrial natriuretic peptide-induced vascular hyperpermeability and loss of plasma volume.

Authors:  Yueh-Chen Lin; Haris Samardzic; Roger H Adamson; Eugene M Renkin; Joyce F Clark; Rolf K Reed; Fitz-Roy E Curry
Journal:  J Physiol       Date:  2010-11-22       Impact factor: 5.182

Review 4.  Guanylyl cyclase / atrial natriuretic peptide receptor-A: role in the pathophysiology of cardiovascular regulation.

Authors:  Kailash N Pandey
Journal:  Can J Physiol Pharmacol       Date:  2011-08-04       Impact factor: 2.273

Review 5.  The functional genomics of guanylyl cyclase/natriuretic peptide receptor-A: perspectives and paradigms.

Authors:  Kailash N Pandey
Journal:  FEBS J       Date:  2011-04-07       Impact factor: 5.542

6.  Atrial natriuretic peptide genetic variant rs5065 and risk for cardiovascular disease in the general community: a 9-year follow-up study.

Authors:  Valentina Cannone; Brenda K Huntley; Timothy M Olson; Denise M Heublein; Christopher G Scott; Kent R Bailey; Margaret M Redfield; Richard J Rodeheffer; John C Burnett
Journal:  Hypertension       Date:  2013-09-16       Impact factor: 10.190

7.  The heart communicates with the endothelium through the guanylyl cyclase-A receptor: acute handling of intravascular volume in response to volume expansion.

Authors:  Barbara Schreier; Sebastian Börner; Katharina Völker; Stepan Gambaryan; Stephan C Schäfer; Peter Kuhlencordt; Birgit Gassner; Michaela Kuhn
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

Review 8.  Genetic variation in the natriuretic peptide system and heart failure.

Authors:  David E Lanfear
Journal:  Heart Fail Rev       Date:  2008-10-11       Impact factor: 4.214

Review 9.  Central role of guanylyl cyclase in natriuretic peptide signaling in hypertension and metabolic syndrome.

Authors:  G Martel; P Hamet; Johanne Tremblay
Journal:  Mol Cell Biochem       Date:  2009-11-25       Impact factor: 3.396

10.  Atrial natriuretic peptide modulation of albumin clearance and contrast agent permeability in mouse skeletal muscle and skin: role in regulation of plasma volume.

Authors:  Fitz-Roy E Curry; Cecilie Brekke Rygh; Tine Karlsen; Helge Wiig; Roger H Adamson; Joyce F Clark; Yueh-Chen Lin; Birgit Gassner; Frits Thorsen; Ingrid Moen; Olav Tenstad; Michaela Kuhn; Rolf K Reed
Journal:  J Physiol       Date:  2009-11-30       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.